Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.5K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.2K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.6K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

6.9K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on Wages et al, Coherence principles in interval-based dose finding. Pharmaceutical Statistics 2019, doi:10.1002/pst.1974.

Pharmaceutical statistics·2020
Same author

Dose Titration Algorithm Tuning (DTAT) should supersede 'the' Maximum Tolerated Dose (MTD) in oncology dose-finding trials.

F1000Research·2017
Same author

Casting a realist's eye on the real world of medicine: Against Anjum's ontological relativism.

Journal of evaluation in clinical practice·2017
Same journal

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Automated Pharmacometric Model Development by Leveraging Low-Dimensional Neural ODEs and LASSO Regression.

CPT: pharmacometrics & systems pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jul 17, 2025

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.6K

How large must a dose-optimization trial be?

David C Norris1

  • 1Precision Methodologies, LLC, Wayland, Massachusetts, USA.

CPT: Pharmacometrics & Systems Pharmacology
|September 5, 2023
PubMed
Summary
This summary is machine-generated.

New US FDA guidance for cancer drug dose optimization trials may require hundreds of participants. Statistical principles are needed to ensure trial precision and account for patient variability in drug effects and treatment preferences.

More Related Videos

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

10.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Related Experiment Videos

Last Updated: Jul 17, 2025

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.6K
Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

10.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Area of Science:

  • Clinical Trial Design
  • Pharmacometrics
  • Oncology Drug Development

Background:

  • US Food and Drug Administration Oncology Center of Excellence (OCE) recommends randomized, parallel dose-response trials for dose optimization.
  • Current draft guidance lacks specific statistical principles for trial design and precision.
  • Interindividual heterogeneity in pharmacokinetics/pharmacodynamics and efficacy-toxicity trade-offs is a key challenge.

Purpose of the Study:

  • To propose a criterion for reasonable precision in dose-response trials.
  • To examine the implications of this criterion for minimum participant enrollment.
  • To incorporate a utility-based framework addressing patient variability.

Main Methods:

  • Development of a precision criterion for dose-response trials.
  • Application of a utility-based framework accounting for pharmacokinetic/pharmacodynamic heterogeneity.
  • Analysis of subjective efficacy-toxicity trade-off evaluations.

Main Results:

  • Even under ideal conditions, trials may require substantial participant enrollment.
  • The proposed criterion highlights the need for robust statistical planning.
  • Significant sample sizes are indicated for achieving precise dose-optimization estimates.

Conclusions:

  • The statistical principles for designing effective dose-optimization trials need further clarification.
  • Achieving reasonable precision in oncology dose-response trials necessitates careful consideration of sample size.
  • Future trial designs should integrate patient heterogeneity to ensure meaningful results.